Metabolised by CYP2C8 and 2E1 0-dealkylation. No data pointing to CYP-induction. Did not induce ALAS1 in rat. Two references consider it safe to use. Considerable clinical evidence of non-porphyrinogenicity.

(To be edited, initial data ST OCT 04) Tabl 250-1000 mg/d. Analgetic and antiflogistic propionic acid derivative. About 30% is metabolized to 6-0-desmethyl derivative by CYP2E1 and 2C8. Inhibitor of CYP 2E1. No data pointing to CYP-induction South African list: use. French list: authorized. C.Andersson; patient reports: tolerated (n=10).

Uneventful use reported in 82 patients with acute porphyria.